Evaluation of Cholinergic Deficiency in Preclinical Alzheimer's Disease Using Pupillometry
暂无分享,去创建一个
Yogesan Kanagasingam | David Ames | Christopher C Rowe | Colin L Masters | Shaun Frost | Kevin Taddei | C. Rowe | R. Martins | C. Masters | D. Ames | K. Taddei | S. Rainey-Smith | S. Frost | Y. Kanagasingam | Ralph N Martins | Liam Robinson | Stephanie R Rainey-Smith | Liam Robinson | Shaun Frost
[1] Helmut Wilhelm,et al. Clinical applications of pupillography. , 2003, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.
[2] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[3] Bruno Dubois,et al. Cholinergic deficiency and frontal dysfunction in Parkinson's disease , 1990, Annals of neurology.
[4] Charles D. Smith,et al. Neuropathologic substrate of mild cognitive impairment. , 2006, Archives of neurology.
[5] Satoshi Takahashi,et al. Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia , 1994, Neuroscience Letters.
[6] H. Braak,et al. Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.
[7] M. J. Wade,et al. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. , 2001, Archives of neurology.
[8] J. Michael. Textbook of Medical Physiology , 2005 .
[9] A Tales,et al. The pupillary light reflex in aging and Alzheimer's disease. , 2001, Aging.
[10] Karl Herholz,et al. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease , 2004, NeuroImage.
[11] P. Davies,et al. SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.
[12] J. Morris,et al. Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease , 1996, The Journal of Neuroscience.
[13] Trey Sunderland,et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.
[14] D. Mash,et al. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. , 1998, Journal of neuropathology and experimental neurology.
[15] Gina N. LaRossa,et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.
[16] Chrysa D. Lithari,et al. Cholinergic deficiency in Alzheimer's and Parkinson's disease: evaluation with pupillometry. , 2009, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.
[17] K. Rhodes,et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.
[18] C. Rowe,et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.
[19] J. Morris,et al. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.
[20] E. Salmon,et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.
[21] Bruno Vellas,et al. Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force , 2013, Alzheimer's & Dementia.
[22] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[23] W. Markesbery,et al. Neuropathologic alterations in mild cognitive impairment: a review. , 2010, Journal of Alzheimer's disease : JAD.
[24] E. Szabadi,et al. Altered pupillary size and darkness and light reflexes in Alzheimer's disease. , 1997, Journal of Neurology Neurosurgery & Psychiatry.
[25] C. Jack,et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.
[26] Lennart Thurfjell,et al. Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.
[27] E. Tangalos,et al. Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .
[28] Aaas News,et al. Book Reviews , 1893, Buffalo Medical and Surgical Journal.
[29] M. Molaschi,et al. Is videopupillography useful in the diagnosis of Alzheimer's disease? , 1998, Neurology.
[30] Yogesan Kanagasingam,et al. Pupil response biomarkers for early detection and monitoring of Alzheimer's disease. , 2013, Current Alzheimer research.
[31] Eric M Reiman,et al. The Role of Biomarkers in Clinical Trials for Alzheimer Disease , 2006, Alzheimer disease and associated disorders.
[32] M. Bobinski,et al. Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.
[33] Eric Granholm,et al. Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease. , 2003, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.
[34] M. Tsolaki,et al. Changes in pupil reaction to light in Alzheimer's disease patients: a preliminary report. , 2000, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.
[35] S Ourselin,et al. β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia , 2010, Neurology.
[36] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[37] W. Marsden. I and J , 2012 .
[38] Anna-Bettina Haidich,et al. Pupil reaction to light in Alzheimer’s disease: evaluation of pupil size changes and mobility , 2007, Aging clinical and experimental research.
[39] M. Weiner,et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.
[40] C. Rowe,et al. Age dependent prevalence of beta-amyloid positive 11C-PiB PET in healthy elderly subjects parallels neuropathology findings , 2008 .
[41] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.
[42] A. Fagan,et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.
[43] C. Rowe,et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.